Cargando…

Metabolic features of orbital adipose tissue in patients with thyroid eye disease

BACKGROUND: Thyroid eye disease (TED) is the most frequent orbital disease in adults and is characterized by the accumulation of orbital adipose tissue (OAT). It can lead to eyelid retraction or even vision loss. Orbital decompression surgery serves as the primary treatment for inactive TED by remov...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Rui, Wang, Fenfen, Yang, Chun, Hu, Jing, Liu, Jiapei, Jian, Qizhi, Wang, Ruonan, Zhang, Jian, Chen, Hui, Wang, Yufan, Zhang, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435847/
https://www.ncbi.nlm.nih.gov/pubmed/37600696
http://dx.doi.org/10.3389/fendo.2023.1151757
_version_ 1785092196378083328
author Du, Rui
Wang, Fenfen
Yang, Chun
Hu, Jing
Liu, Jiapei
Jian, Qizhi
Wang, Ruonan
Zhang, Jian
Chen, Hui
Wang, Yufan
Zhang, Fang
author_facet Du, Rui
Wang, Fenfen
Yang, Chun
Hu, Jing
Liu, Jiapei
Jian, Qizhi
Wang, Ruonan
Zhang, Jian
Chen, Hui
Wang, Yufan
Zhang, Fang
author_sort Du, Rui
collection PubMed
description BACKGROUND: Thyroid eye disease (TED) is the most frequent orbital disease in adults and is characterized by the accumulation of orbital adipose tissue (OAT). It can lead to eyelid retraction or even vision loss. Orbital decompression surgery serves as the primary treatment for inactive TED by removing the excess OAT. However, there is a lack of alternative treatments to surgery due to the unclear understanding of the pathogenesis, particularly the metabolic features. Accordingly, our study was implemented to explore the content and features of metabolites of OATs from TED patients. METHOD: The OATs used in the current study were obtained from the orbital decompression surgery of seven patients with inactive TED. We also collected control OATs from eye surgical samples of five individuals with no history of autoimmune thyroid diseases, TED, or under non-inflammatory conditions. The liquid chromatography mass spectrometer was used for the measurements of the targeted metabolites. Afterwards, we performed differential metabolite assay analysis and related pathway enrichment analysis. RESULTS: In our study, a total of 149 metabolite profiles were detected in all participants. There were significant differences in several metabolite profiles between the TED group and the control group, mainly including uric acid, oxidized glutathione, taurine, dGMP, oxidized glutathione 2, uracil, hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, and uridine 5′-monophosphate (all p-value < 0.05). The TED-related pathways identified included purine metabolism, beta-alanine metabolism, glutathione metabolism (p-values < 0.05). Our study found overlaps and differences including uric acid and uracil, which are in accordance with metabolites found in blood of patients with TED from previous study and several newly discovered metabolite by our study such as hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, compared to those tested from blood, OAT, or urine samples reported in previous studies. CONCLUSION: The findings of our study shed light on the metabolic features of OAT in individuals with TED. These results may help identify new treatment targets for TED, providing potential avenues for developing alternative treatments beyond ophthalmic surgery.
format Online
Article
Text
id pubmed-10435847
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104358472023-08-19 Metabolic features of orbital adipose tissue in patients with thyroid eye disease Du, Rui Wang, Fenfen Yang, Chun Hu, Jing Liu, Jiapei Jian, Qizhi Wang, Ruonan Zhang, Jian Chen, Hui Wang, Yufan Zhang, Fang Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Thyroid eye disease (TED) is the most frequent orbital disease in adults and is characterized by the accumulation of orbital adipose tissue (OAT). It can lead to eyelid retraction or even vision loss. Orbital decompression surgery serves as the primary treatment for inactive TED by removing the excess OAT. However, there is a lack of alternative treatments to surgery due to the unclear understanding of the pathogenesis, particularly the metabolic features. Accordingly, our study was implemented to explore the content and features of metabolites of OATs from TED patients. METHOD: The OATs used in the current study were obtained from the orbital decompression surgery of seven patients with inactive TED. We also collected control OATs from eye surgical samples of five individuals with no history of autoimmune thyroid diseases, TED, or under non-inflammatory conditions. The liquid chromatography mass spectrometer was used for the measurements of the targeted metabolites. Afterwards, we performed differential metabolite assay analysis and related pathway enrichment analysis. RESULTS: In our study, a total of 149 metabolite profiles were detected in all participants. There were significant differences in several metabolite profiles between the TED group and the control group, mainly including uric acid, oxidized glutathione, taurine, dGMP, oxidized glutathione 2, uracil, hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, and uridine 5′-monophosphate (all p-value < 0.05). The TED-related pathways identified included purine metabolism, beta-alanine metabolism, glutathione metabolism (p-values < 0.05). Our study found overlaps and differences including uric acid and uracil, which are in accordance with metabolites found in blood of patients with TED from previous study and several newly discovered metabolite by our study such as hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, compared to those tested from blood, OAT, or urine samples reported in previous studies. CONCLUSION: The findings of our study shed light on the metabolic features of OAT in individuals with TED. These results may help identify new treatment targets for TED, providing potential avenues for developing alternative treatments beyond ophthalmic surgery. Frontiers Media S.A. 2023-08-03 /pmc/articles/PMC10435847/ /pubmed/37600696 http://dx.doi.org/10.3389/fendo.2023.1151757 Text en Copyright © 2023 Du, Wang, Yang, Hu, Liu, Jian, Wang, Zhang, Chen, Wang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Du, Rui
Wang, Fenfen
Yang, Chun
Hu, Jing
Liu, Jiapei
Jian, Qizhi
Wang, Ruonan
Zhang, Jian
Chen, Hui
Wang, Yufan
Zhang, Fang
Metabolic features of orbital adipose tissue in patients with thyroid eye disease
title Metabolic features of orbital adipose tissue in patients with thyroid eye disease
title_full Metabolic features of orbital adipose tissue in patients with thyroid eye disease
title_fullStr Metabolic features of orbital adipose tissue in patients with thyroid eye disease
title_full_unstemmed Metabolic features of orbital adipose tissue in patients with thyroid eye disease
title_short Metabolic features of orbital adipose tissue in patients with thyroid eye disease
title_sort metabolic features of orbital adipose tissue in patients with thyroid eye disease
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435847/
https://www.ncbi.nlm.nih.gov/pubmed/37600696
http://dx.doi.org/10.3389/fendo.2023.1151757
work_keys_str_mv AT durui metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT wangfenfen metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT yangchun metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT hujing metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT liujiapei metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT jianqizhi metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT wangruonan metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT zhangjian metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT chenhui metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT wangyufan metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease
AT zhangfang metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease